1 2 3	IS SHORT-TERM ACYCLOVIR TREATMENT RELATED WITH MORE UNFAVOURABLE OUTCOMES IN PATIENTS WITH HSV-1 ENCEPHALITIS?
4 5	Ferhat Arslan <sup>1</sup> , Ravza Akgündüz <sup>1</sup> , Abdülkadir Ermiş <sup>2</sup> , Begüm Bektaş <sup>1</sup> , Ebru Erbayat <sup>2</sup> , Haluk Vahaboğlu <sup>1</sup>
6	
7	1. Department of Infectious Diseases, Istanbul Medeniyet University, Faculty of
8	Medicine, Istanbul, Turkey
9	2. Department of Neurology, Istanbul Medipol University, Faculty of Medicine,
10	Istanbul, Turkey
11	
12	Corresponding author: Ferhat Arslan, Associate Professor
13	Email addresses: ferhatarslandr@hotmail.com
14	Department of Infectious Diseases, Istanbul Medeniyet University, Faculty of Medicine, Prof.
15	Dr. Süleyman Yalcın Training and Research Hospital, Kadıköy, İstanbul
16	Data availability : If request it will be sent to the editors
17	Conflicts of Interest and Source of Funding: Authors have no competing interests to
18	declare and not received any fund.
19	Ethics approval statement: Ethics committee approval was obtained from the ethics
20	committee of Istanbul Medeniyet University.
21	Patient consent statement: In tertiary hospitals at Turkey, all admitted patients sign the
22	consent form to publish their medical knowledge for scientific purposes.
23	

1

24	Ferhat Arslan:	Conceptualization,	Methodology,	Writing-	Original	draft prepar	ration.	Ravza
----	----------------	--------------------	--------------	----------	----------	--------------	---------	-------

- 25 Akgündüz: Data curation, Investigation. Abdülkadir Ermiş: Data curation, Investigation.
- 26 Begüm Bektaş: Data curation: Ebru Erbayat: Writing- Reviewing and Editingi, Haluk
- 27 Vahaboğlu:Supervision
- 28 ABSTRACT
- 29 Background
- 30 Herpes simplex encephalitis (HSE) is the most common form of sporadic encephalitis which
- 31 is caused by herpes simplex virus type 1 (HSV-1). Current guidelines recommend intravenous
- 32 Acyclovir for 14–21 days in cases of HSE.

# 33 **Objectives**

- 34 Optimizing the Acyclovir treatment duration is important in regards to preventing Acyclovir-
- 35 related neurotoxicity and nephrotoxicity.

## 36 Study design

37 We retrospectively evaluated 13 patients, who were diagnosed with HSE by molecular testing

38 (HSV-1 PCR positivity in cerebrospinal fluid), in two university hospitals in Istanbul,

- between 2010 and 2021. The patients were treated either 10 days or less as a short-term
- 40 treatment regimen of Acyclovir or for 14 days or more as long-term treatment regimen
- 41

# 42 Results

- 43 The median age was 58 years (range 24–82 years) and 54% of them were male. The median
- follow-up time was 79 days (range 20-670 days) after discharge. Long-term treatment was
- 45 used in 6 and a short-term treatment regimen was used in 7 cases. One of the patients died on
- the 4th day of Acyclovir treatment. One patient never received Acyclovir treatment. Of the 5
- 47 patients who received long-term treatment, 3 (21-28 days) had amnesia and orientation-

48	cooperation restriction, one (21 days) died on the 2nd day of treatment, while the other (14
49	days) had no sequelae. There were no sequelae in three out of 5 patients who received short-
50	term treatment.
51	Conclusions
52	We believe that it is necessary to determine the optimal Acyclovir therapy duration should be
53	evaluated in a prospective randomized clinical trial in large patient population.
54	Key words: Herpes simplex virus ; Encephalitis; Acyclovir; Antiviral treatment; Antivirals
55	
56 57	INTRODUCTION
58	Herpes simplex encephalitis (HSE) is the most common form of sporadic encephalitis which
59	is caused by herpes simplex virus type 1 (HSV-1). HSV-1 generally infects orolabial mucosa
60	and face skin epithelium, gains access to neuronal axonal ending, and then is transported to
61	the trigeminal ganglia (TG) <sup>1</sup> . It is estimated approximately 200 million recurrent HSV-1
62	related infections develop every year <sup>2</sup> . However, very few of these cases are HSE. The
63	rareness might be due to its different ways of inoculation in the brain and TG or due to the
64	primary infection rather than reactivation <sup>3</sup> . Despite the increasing knowledge, there are still
65	unclear points in the pathogenesis of HSE.
66	Although it was reported that the mortality rates were above 70% and the rates of
<b>67</b>	

neurological sequelae were around 90%, it has now been decreased to 30% for both mortality
and severe neurological sequelae<sup>4</sup>. Mortality rates have decreased significantly by the
discovery of Acyclovir, improvements in radiological screening (cranial magnetic resonance
imaging), and the use of molecular (HSV-1 DNA) diagnostic methods in medical practice.
Vidarabine was used as a comparative drug in two double-blind, randomized controlled
clinical trials investigating the efficacy and side effects of Acyclovir treatment for HSE<sup>5,6</sup>.

The duration of Acyclovir treatment was ten days in these trials. However, current guidelines recommend intravenous Acyclovir for 14–21 days in cases of HSE<sup>7.8</sup>. Optimizing the Acyclovir treatment duration is important in regards to preventing Acyclovir-related neurotoxicity and nephrotoxicity <sup>9</sup>. Here, we aimed to discuss the recommended treatment durations in patients with HSE by using short-term versus long-term acyclovir treatment. We also emphasize the effects of adjunctive therapies, such as steroids and antibiotics, on these cases.

# **80 MATERIALS AND METHODS**

81 **Patients** 

82

83 We retrospectively evaluated 13 patients, who were diagnosed with HSE by molecular testing 84 (HSV-1 PCR positivity in cerebrospinal fluid), in two university hospitals in Istanbul, 85 between 2010 and 2021. Their clinical (altered mental status, seizures or focal neurological 86 symptoms) and radiological findings (detection of lesions in diffusion or contrast-enhanced 87 MRI), were analyzed. The patients were treated either 10 days or less as a short-term 88 treatment regimen of Acyclovir or for 14 days or more as long-term treatment regimen. 89 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used for the 90 assessment of the renal damage for each case.

91 Ethics committee approval was obtained from the ethics committee of Istanbul Medeniyet92 University.

93 The neurological status for each case was noted from the outpatient follow-up records. 94 Neurological sequelae have been defined as any damage to the central nervous system that 95 results in cognitive, sensory, or motor deficits, which may also manifest as long-term 96 emotional instability and seizures in severe cases<sup>10</sup>.

97

# 98 **RESULTS**

99

# 100 Clinical and MRI features

101

102 A summary of the clinical information of 13 patients is shown in **Table 1**.

103 The median age was 58 years (range 24-82 years) and 54% of them were male. The median 104 follow-up time was 79 days (range 20-670 days) after discharge. Five patients had an 105 underlying disease-causing immune deficiency: Two had organ tumors (Lung cancer and 106 prostate cancer, other two patients had Diabetes mellitus, which one of them with febrile 107 neutropenia due to hemophagocytic syndrome and one patient had recurrent orolabial Herpes 108 reactivation at the time of the diagnosis. The median duration of diagnosis, starting from the symptom onset was 5 days (IQR 5 days Q3:8 Q1:3 IQR:5). The CSF analysis showed 109 110 lymphocytic pleocytosis in 9/13 patients (median leukocyte count 161 cells/mL, range 0-500), and elevated protein concentration in 10/13 (median 91 mg/dL, range 35-349) 111 112 While unconsciousness was observed in all of the patients, no neck stiffness was found in any 113 of them. On admission, fever (9/13), headache (9/13), seizures (7/13) and focal neurological signs (diplopia and hearing loss in 1 patient and right hemiparesis in another patient) were 114 115 noted.

In all patients, the clinical diagnosis of HSE was confirmed by the MRI findings of unilateral
(9 patients) or bilateral (3 patients) increased fluid-attenuated inversion recovery (FLAIR)/T2
signal abnormalities in temporal regions. In five patients, frontal (2 patients), hippocampal (2
patients) and occipital (1 patient) FLAIR/T2 signal abnormalities were additionally observed.

120

#### 121 Treatment

Long-term treatment was used in 6 and a short-term treatment regimen was used in 7 cases. One of the patients died on the 4th day of Acyclovir treatment. One patient never received Acyclovir treatment. Twelve patients had also broad-spectrum antibiotic treatment at the beginning. Adjunctive steroid therapy was given in 3 patients. Antiepileptic therapy was needed for 10 patients. Treatment modalities and follow-up of renal functions are summarized in **Table 2** 

128 Outcomes

129

130 Death occurred in 2 patients. One of them was already on severe immunosuppressive therapy due to EBV-related hemophagocytosis. The other patient had lung cancer with brain 131 132 metastases and subarachnoid hemorrhage. Of the 5 patients who received long-term treatment, 133 3 (21-28 days) had amnesia and orientation-cooperation restriction, one (21 days) died on the 134 2nd day of treatment, while the other (14 days) had no sequelae. There were no sequelae in 135 three out of 5 patients who received short-term treatment, however, balance problems 136 continued in one of them in 6 months after treatment. Neurological sequelae did not develop 137 in the patient who did not receive any treatment. CKD-EPI decrease associated with renal 138 failure was seen only in one patient.

139

# 140 **DISCUSSION**

141

There is a solid consensus for the early initiation of effective antiviral agents in HSE, however, recommendations regarding the duration of the antiviral treatment is still at the level of expert opinion. Although this is a case series study and it is consisted of a small number of cases, we observed some interesting results: In short term Acyclovir treatment group, CNS symptoms of all 6 patients improve within the first week of the drug discontinuation, contrary

147 to the long-term treatment group, where the symptoms and signs of the HSE continued after 148 the discontinuation. In another word, neurological sequelae in long-term treatment group were 149 more common than the short-term treatment group. Additionally, the patients who received 150 steroid treatments from both groups (patient 1,6,7,10) did not reveal any neurological 151 deterioration. Seizure in one patient in 26th month and progressive amnesia in another patient 152 on 5th month of the follow-up after short term treatment, respectively. Interestingly, 153 neurological sequelae did not develop in the patient (patient 2 who was not given acyclovir 154 treatment. One out of patients were treated with empirical antibiotics. Our observations may 155 encourage steroid and short-term Acyclovir therapy in the management of the patients with 156 HSE.

157

Stevens et al. showed that HSV viral replication continued for up to 8 days in a spinal 158 ganglion of animal model study<sup>11</sup>. In a superior cervical ganglia (SCG) cell cultures-based 159 160 HSV-1 model study, it was shown that phase 1 and phase 2 transcriptional processes take place in less than 5 days<sup>12</sup>. Toll like receptor 3 (TLR-3) dependent production of IFN- $\alpha/\beta$  and 161 IFN- $\lambda$  is seen as a protective factor for HSE in children<sup>13</sup>. Additionally, Acyclovir doesn't 162 163 have an inhibitor effect on the replication of the HSV-1 in human neural cell lines without human interferon-alpha (IFN-alpha)<sup>14</sup>. IFN- $\beta$  treatment in baby mice with HSV encephalitis 164 model decreased neuro-invasion and increase the survival rate<sup>15</sup>. We may conclude that the 165 166 combined effect of Acyclovir implementation and host interferon response can be achieved 167 only at the early days of the HSE. In our study, the median time from symptoms onset to 168 treatment initiation was 3.4 days in the group receiving short-term acyclovir treatment, while 169 it is 6.6 days in the group receiving long-term treatment. This may contribute to the low rate 170 of neurological sequelae in the group receiving short-term treatment.

171 Other probable justifications have been put forward for long-term antiviral treatment 172 rationale. In situ low-level HSV-1 replication hypothesis examined in the prospective 173 randomized double-blind study of Gnann et al, long-term Valacyclovir treatment was found to have no significant effect on neurological outcome<sup>16</sup>. The second issue is the assumed 174 175 virological relapse that may be seen after the early cessation of acyclovir. In a long-term study 176 of 32 adult HSE cases prospectively observed, HSE relapse was reported in 4 patients. 177 However, HSV PCR positivity was not detected in any of the 12 CSF samples taken from 178 these patients. It has been reported that putative relapses occur within the first 4 months after 179 infection<sup>17</sup>. It was reported that HSV-1 antigen and HSV-1 DNA were detected 180 immunohistochemically in the necrotic right frontal and parietal lobe samples from the autopsy of a patient who presented with status epilepticus 5 years after  $HSE^{18}$ . The authors 181 182 claim that this case is the first pathologically and molecularly confirmed relapse of HSE in the 183 medical literature. However, progressive neurological deterioration throughout 5 years in the 184 course of the case raises questions about whether the patient is in a relapse or a chronic autoimmune process<sup>19,20</sup>. 185

186 During the SARS-CoV-2 pandemic, there has been increased awareness about the possible antiviral effects of some drugs that are not used as virucidal<sup>21</sup>. Empirical antibiotics and 187 188 steroids along with the Acyclovir treatment is a quite common clinical approach to the HSE cases in the first days before definitive diagnosis<sup>22</sup>. Inhibitory activity of Cephalosporin 189 derivatives on HSV-1 was shown in vitro<sup>23</sup>. Similarly, some other molecules (Valproic acid, 190 191 Valpromide and Valnoctamide) that inhibit the replication of HSV-1 virus in oligodendrocytes have been identified<sup>24</sup>. The researchers emphasized that these molecules 192 193 could be an effective and safe treatment alternatives in HSE. The effect of non-antiviral drugs, 194 especially antibiotics on HSE prognosis has not been studied.

195 Researchers have developed human induced pluripotent stem cells (hiPSCs) and neuronal cells based on 3D organoid models to establish HSV-1 infections<sup>25</sup>. Although in vitro 196 197 establishment of neuron cells infection has been shown, there are in vivo differences. HSV-1 has evolved latency mechanisms to stay in neuron cells in order to escape from immunity<sup>26</sup>. 198 199 Due to the logic of co-evolution, the relationship between HSV and neuronal cells cannot be 200 considered to be direct damage (cytopathic damage). The important question here is which cells are susceptible for HSV-1 replication in brain<sup>27</sup>. As we understand from the CSF finding, 201 erythrocytosis, the blood-brain barrier (BBB) is disrupted in HSE patients<sup>28</sup>. Brain 202 203 microvascular endothelial cells may play the primary role in neuronal damage due to HSV-1 204 induced endothelial cell adhesion molecules that interact with lymphocytes and neutrophils recruitment<sup>29,30</sup>. We may speculate that steroids may play a role to diminish this recruitment 205 and decrease the vascular inflammation as adjunctive therapy. Adjunctive steroid therapy 206 initiation timing and its duration are still elusive<sup>31</sup>. 207

In conclusion, the optimal duration of antiviral treatment for HSE is still a controversial issue. Those who received short-term treatment might not have worse outcome than those who received long-term treatment in terms of neurological sequelae. We believe that it is necessary to determine the optimal Acyclovir therapy duration, as well as the steroids' effect on probable vasculitis and should be tested in a prospective randomized clinical trial in large patient population.

214

215

216

217

# 218 **REFERENCES**

- Sawtell NM, Thompson RL. Alphaherpesvirus Latency and Reactivation with a Focus on Herpes Simplex Virus. *Curr Issues Mol Biol*. 2020;41:267-356. doi:10.21775/cimb.041.267
- James C, Harfouche M, Welton NJ, et al. Herpes simplex virus: global infection
   prevalence and incidence estimates, 2016. *Bull World Health Organ*. 2020;98(5):315 329. doi:10.2471/BLT.19.237149
- 3. Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? *Curr Opin Neurol.* 2011;24(3):268-274. doi:10.1097/WCO.0b013e328346be6f
- McGrath N, Anderson NE, Croxson MC, Powell KF. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. *J Neurol Neurosurg Psychiatry*. 1997;63(3):321-326. doi:10.1136/jnnp.63.3.321
- Sköldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes
   simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.
   *Lancet Lond Engl.* 1984;2(8405):707-711. doi:10.1016/s0140-6736(84)92623-0
- Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes
   simplex encephalitis. *N Engl J Med.* 1986;314(3):144-149.
   doi:10.1056/NEJM198601163140303
- Tunkel AR, Glaser CA, Bloch KC, et al. The Management of Encephalitis: Clinical
   Practice Guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*.
   2008;47(3):303-327. doi:10.1086/589747
- Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in adults – Association of British Neurologists and British Infection Association National Guidelines. *J Infect*. 2012;64(4):347-373. doi:10.1016/j.jinf.2011.11.014
- Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of
  the literature. *South Med J*. 1994;87(12):1227-1231. doi:10.1097/00007611-19941200000006
- Ronca SE, Dineley KT, Paessler S. Neurological Sequelae Resulting from Encephalitic
   Alphavirus Infection. *Front Microbiol.* 2016;7:959. doi:10.3389/fmicb.2016.00959
- 11. Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia of mice. *Science*.
  1971;173(3999):843-845. doi:10.1126/science.173.3999.843
- Kim JY, Mandarino A, Chao MV, Mohr I, Wilson AC. Transient reversal of episome
   silencing precedes VP16-dependent transcription during reactivation of latent HSV-1 in
   neurons. *PLoS Pathog*. 2012;8(2):e1002540. doi:10.1371/journal.ppat.1002540
- Lafaille FG, Pessach IM, Zhang S-Y, et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. *Nature*. 2012;491(7426):769-773. doi:10.1038/nature11583

25 25 25	6	Hanada N, Kido S, Kuzushima K, Goto Y, Rahman MM, Morishima T. Combined effects of acyclovir and human interferon-alpha on herpes simplex virus replication in cultured neural cells. <i>J Med Virol</i> . 1989;29(1):7-12. doi:10.1002/jmv.1890290103
25 25 26 26	9 0	Giraldo D, Wilcox DR, Longnecker R. The Innate Immune Response to Herpes Simplex Virus 1 Infection Is Dampened in the Newborn Brain and Can Be Modulated by Exogenous Interferon Beta To Improve Survival. <i>mBio</i> . 2020;11(3). doi:10.1128/mBio.00921-20
26 26 26	3	Gnann JW Jr, Sköldenberg B, Hart J, et al. Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy. <i>Clin Infect Dis</i> . 2015;61(5):683-691. doi:10.1093/cid/civ369
26 26 26	6	Sköldenberg B, Aurelius E, Hjalmarsson A, et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. <i>J Neurol</i> . 2006;253(2):163-170. doi:10.1007/s00415-005-0941-6
26 26 27	9	Yamada S, Kameyama T, Nagaya S, Hashizume Y, Yoshida M. Relapsing herpes simplex encephalitis: pathological confirmation of viral reactivation. <i>J Neurol Neurosurg Psychiatry</i> . 2003;74(2):262-264. doi:10.1136/jnnp.74.2.262
27 27 27 27	2 3	Schein F, Gagneux-Brunon A, Antoine J-C, et al. Anti-N-methyl-D-aspartate receptor encephalitis after Herpes simplex virus-associated encephalitis: an emerging disease with diagnosis and therapeutic challenges. <i>Infection</i> . 2017;45(4):545-549. doi:10.1007/s15010-016-0959-y
27 27 27	6	Armangue T, Leypoldt F, Málaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. <i>Ann Neurol</i> . 2014;75(2):317-323. doi:https://doi.org/10.1002/ana.24083
27 27 28	9	Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. <i>Nature</i> . 2020;583(7816):459-468. doi:10.1038/s41586-020-2286-9
28 28 28 28 28 28	2 3 4	Hagen A, Eichinger A, Meyer-Buehn M, Schober T, Huebner J. Comparison of antibiotic and acyclovir usage before and after the implementation of an on-site FilmArray meningitis/encephalitis panel in an academic tertiary pediatric hospital: a retrospective observational study. <i>BMC Pediatr</i> . 2020;20(1):56. doi:10.1186/s12887-020-1944-2
28 28 28	7	Cottagnoud P, Neftel KA, Hany M, Zinkernagel RM. Inhibition of HSV-1 and vaccinia virus replication by cephalosporin derivatives. <i>Antiviral Res.</i> 1988;10(1):59-70. doi:10.1016/0166-3542(88)90014-9
28 29 29	0	Praena B, Bello-Morales R, de Castro F, López-Guerrero JA. Amidic derivatives of valproic acid, valpromide and valnoctamide, inhibit HSV-1 infection in oligodendrocytes. <i>Antiviral Res.</i> 2019;168:91-99. doi:10.1016/j.antiviral.2019.05.006
29 29 29 29	3 4	D'Aiuto L, Bloom DC, Naciri JN, et al. Modeling Herpes Simplex Virus 1 Infections in Human Central Nervous System Neuronal Cells Using Two- and Three-Dimensional Cultures Derived from Induced Pluripotent Stem Cells. <i>J Virol</i> . 2019;93(9). doi:10.1128/JVI.00111-19

296 297 298	26.	Kalamvoki M, Du T, Roizman B. Cells infected with herpes simplex virus 1 export to uninfected cells exosomes containing STING, viral mRNAs, and microRNAs. <i>Proc Natl Acad Sci U S A</i> . 2014;111(46):E4991-4996. doi:10.1073/pnas.1419338111
299 300 301	27.	Bello-Morales R, Fedetz M, Alcina A, Tabarés E, López-Guerrero JA. High susceptibility of a human oligodendroglial cell line to herpes simplex type 1 infection. <i>J Neurovirol</i> . 2005;11(2):190-198. doi:10.1080/13550280590924179
302 303 304	28.	Liu H, Qiu K, He Q, Lei Q, Lu W. Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis. <i>J Neuroimmune Pharmacol Off J Soc NeuroImmune</i> <i>Pharmacol</i> . 2019;14(2):157-172. doi:10.1007/s11481-018-9821-6
305 306 307	29.	Brankin B, Hart MN, Cosby SL, Fabry Z, Allen IV. Adhesion molecule expression and lymphocyte adhesion to cerebral endothelium: effects of measles virus and herpes simplex 1 virus. <i>J Neuroimmunol</i> . 1995;56(1):1-8. doi:10.1016/0165-5728(94)00110-a
308 309 310	30.	Michael BD, Bricio-Moreno L, Sorensen EW, et al. Astrocyte- and Neuron-Derived CXCL1 Drives Neutrophil Transmigration and Blood-Brain Barrier Permeability in Viral Encephalitis. <i>Cell Rep.</i> 2020;32(11):108150. doi:10.1016/j.celrep.2020.108150
311 312	31.	Piret J, Boivin G. Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis. <i>Clin Microbiol Rev.</i> 2020;33(2). doi:10.1128/CMR.00105-19

313

# TABLE 1: CLINICAL FEATURES OF PATIENTS WITH HERPES SIMPLEX ENCEPHALITIS (HSE) WHO RECIEVED ACYCLOVIR TREATMENT 314 315 316 317

	Age range /Sex	Symptoms	Signs	Cranial MRI findings	CSF PCR	Time to Treatment <sup>®</sup>	Outcome
Patient 1	(50-55)/F	Altered mental status, dysarthria, behavioral changes	Confused, disoriented, limited cooperation	Bilateral insular cortex, right temporal lobe, contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	1 day	No sequelae alive
Patient 2	(80-85)/M	Fever, headache	Lethargy	Right temporal lobe, hippocampal, insular cortex contrast enhancement, and diffusion restriction	CSF HSV Type-1 PCR: Positive	None	No sequelae alive
Patient 3	(75-80)/F	Altered mental status, dysarthria, difficulties on walking	Unconscious GCS=10	Bilateral temporal lobe (right dominant), contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	3 days	No sequelae alive

Patient 4	(40-45)/M	Altered mental status, dysarthria, fever, headache, nausea and vomiting, loss of balance	Confused, disoriented, limited cooperation	Right temporal lobe, parasilviyan, hippocampal and parahippocam pal contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	7 days	N o sequelae alive
Patient 5	(65-70)/F	Fever, Headache, Dysarthria	Confused, disoriented, limited cooperation	Left tem poral lobe, hippocampal, insular cortex contrast enhancement and diffusion restriction	CSF HSV Type-1 PCR: Positive	5 days	N o sequelae alive
Patient 6	(20-25)/F	Fever, headache, altered mental status, nausea and vomiting	Confused, disori ented, limited cooperation	Left tem poral lobe, left insular cortex, uncut and hippocampus gyrus, dorsal thalamus contrast enhancem ent and diffusion restriction	CSF HSV Type-1 PCR: Positive	3 days	Loss of balance, seizures alive
Patient 7	(65-70)/M	Altered mental status, convulsion	Confused, disoriented, limited cooperation	Right temporal lobe, insular cortex T2 hyperintensity and diffusion restriction	CSF HSV Type-1 PCR: Positive	5 days	Dead
Patient 8	(20-25)/F	Fever, Headache, Seizure	Lethargy	Right temporal lobe, insular cortex, thalamus contrast	CSF HSV Type-1 PCR: Positive	3 days	No sequelae alive
				enhancement and diffusion restriction			
Patient 9	(70-75)/M	Altered mental status, headache, vesicular rash	Lethargy	enhancement and diffusion	CSF HSV Type-1 PCR: Positive	10 days	Dead
Patient 9 Paetient 10	(70-75)/M (40-45)M	status, headache,	Lethargy Confused, disoriented, Lethargy diplopia	enhancement and diffusion restriction		10 days 7 days	Dead

Fever, Convulsion       Iimited cooperation       (right dominant), Right Halamus contrast enhancement and diffusion restriction       State of the state o							
status, disoriented, temporal lobe, Positive disoriented, aix Headache, limited contrast behavioral cooperation enhancement changes sensory and diffusion aphasia restriction	Patient 12	(02-10)\M	status, Fever,	disori ented, limited	temporal lobe (right dominant), Right thalamus contrast enhancement and diffusion	4 days	prolonged reaction time to complex orders,
: Time from symptoms onset to treatment initiation	Patient 13	(60-65)/M	status, Headache, behavioral	disoriented, limited cooperation sensory	temporal lobe, contrast enhancement and diffusion	8 days	Confused, disoriented, alive
	<sup>a</sup> : Time from	symptoms on	nset to treatmen	t initiation			

# TABLE 2: TREATMENT MODALITIES AND RENAL FUNCTIONS OF PATIENTS WITH HERPES SIMPLEX ENCEPHALITIS (HSE)

Patients	Empirical antibiotics	Acyclovir start time <sup>a</sup>	Acyclovir duration	Steroid treatment	Antiepileptic treatment	CNS Symptoms resolved time	eGFR(CKD-EPI) on admission	eGFR(CKD-EPI) on discharge
Patient 1	Cefuroxime axetil, Meropenem- Linezolid-INH- Rifampin	1 d	10 d	2 d	1 months after discharge	3 days (AAS)	97	86
Patient 2	Meropenem Linezolid	None	None	None	None	14th days of admission	45	76
Patient 3	Ampicillin	3 d	9 d	None	5 months after discharge	9 days (AAS)	36	55
Patient 4	Ceftriaxone	1 d	7 d	None	2 months after discharge	4 days (AAS)	117	68

Patient 5	Amoxicilline- Clavulanate, Ampicillin- Ceftriaxone	5 d	7 d	None	None	4 days (AAS)	83	55
Patient 6	Ceftriaxone Ampicilline	1 d	10 d	7 d + 20 d	2nd day of hospitalization	3 days (ASI)	127	134
Patient 7	Piperacilline- Tazobactam	5 d	4 d	None	2nd day of symptoms	None	100	112
Patient 8	Ceftriaxone	1 d	14 d	3 d	2nd day of hospitalization	10th days of admission	131	123
Patient 9	Ceftriaxone	1 d	21 d	None	None	12th days of admission	85	82
Patient 10	meropenem	7 d	21 d	10 d	None	14 days (AAS)	70	36
Patient 11	Ceftriaxone	8 d	28 d	None	1st day of hospitalization	5 days (AAS), but confusion perminent	74	95

Patient 12	Ceftriaxone and levofloxacin	4 d	24 d	None	1st day of hospitalization	7 days (AAS) but confusion perminent	81	102
Patient 13	None	8 d	21 d	None	3rd day of hospitalization	3 days (AAS)	72	62

<sup>a</sup>: Time from symptoms onset to treatment initiation

CNS: Central nervous system; AAS: After acyclovir stopped; ASI: After steroid initiation